The young breast cancer patient therapy – new opportunities, new challenges

• Authors: Joanna Załuska-Kusz , Joanna Kufel-Grabowska
• Languages of publication: EN

Abstracts

EN

The paper describes the case of a 31-year-old female patient with breast cancer with the abdominal metastases. This disease in young people usually has a more aggressive biological subtype, which significantly worsens the prognosis. In this patient aggressive treatment was used. It was effective and did not cause severe or long-term complications.

Keywords

EN

breast cancer in young patient; metastatic disease; non-pegylated liposomal doxorubicin; ribociclib

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2019
• Volume: 9
• Issue: 2
• Pages: 51-54

Contributors

author

Joanna Załuska-Kusz

• Department of Chemotherapy, Greater Poland Cancer Center

author

Joanna Kufel-Grabowska

• Department of Electroradiology, Poznan University of Medical Sciences

References

• 1. Batist G, Remakrishnan G, Rao CS et al. Reduced cardiotoxity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin with cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-54.
• 2. Batist G, Harris L, Azarina N et al. Improved anti-tumor response rate with decreased cardiotoxity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who haved received prior adjuvant doxorubicin: results of a retrospective analysys. Anticancer Drugs 2006; 17: 587-95.
• 3. Meiyuan X, Feifei Y, Sufen Y, Peng S. Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized trials. PloS One 2015; 10(7): e0133569

• Document Type: article